Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Centre Hospitalier Universitaire de Tivoli became the third Belgium hospital and the fifteenth European hospital to purchase a Mobetron for IOERT

IntraOp Medical Corporation (OTC:IOPD.PK) (News) announced that the Centre Hospitalier Universitaire de Tivoli (CHU Tivoli) became the third Belgium hospital and the fifteenth European hospital to purchase a Mobetron for Intra-Operative Electron Radiation Therapy (IOERT).

“There is an increasing interest by Belgian hospitals to acquire IOERT capability,” says Guido Dutoit, Director of Dutoit Medical, Intraop Medical ’s partner in the Benelux countries. “The clinical data showing the effectiveness of IOERT for breast cancer compared to the conventional treatment for breast cancer is very convincing, and Belgian hospitals are all looking to provide their patients the best breast cancer treatment possible—and that is IOERT.”

IntraOp Medical ’s Mobetron is a mobile, self-shielded, technology that delivers radiation directly to a tumor site during cancer surgery without having to pass through the surrounding body structures. This procedure is called IOERT. The Mobetron enables radiation and surgical professionals to visually pinpoint the optimal site for radiation by seeing the exposed tumor bed and delivering a concentrated beam of radiation to a specific depth during cancer surgery. Clinical studies involving a number of cancer indications such as head and neck, sarcomas, colorectal, pancreatic, and breast have shown that patients treated with IOERT often have fewer recurrences, which correlates to increased survival.

CHU Tivoli, in the city of La Louvière, is located about 60 km east of Brussels, and is one of the network of health care institutions of the Free University of Brussels. Its radiation oncology department is affiliated with the Institut Jules Bordet, a Mobetron user for the last two years.

John Powers, IntraOp Medical ’s CEO, strongly believes this is a trend that will continue to gain momentum. They recently restructured their long term debt to better position themselves to address this demand. “The increasing demand for the Mobetron and IOERT is evident in Europe where IOERT has had a more than a decade of clinical history for breast cancer with less than 1% recurrence, compared to an average estimate of 7% in the US using conventional treatment. As further results are published, we expect the enthusiasm shown in Western Europe to continue to spread to other parts of the world. We already see this trend as our Mobetron centers in the Far East and five of our U.S. centers are now using or planning to use the Mobetron for the treatment of breast cancer.”

Source: IntraOp Medical Corporation